Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers (original) (raw)

Abstract

Germline mutations of the BRCA2 gene on chromosome 13q12-q13 predispose to the development of early-onset breast cancer and ovarian cancer. Loss of heterozygosity detected using chromosome 13q markers in the vicinity of BRCA2 is observed in most cancers arising in carriers of germline BRCA2 mutations and also in 30-50% of sporadic breast and ovarian cancers. However, somatic mutations of BRCA2 are extremely rare in sporadic cancers. We have examined the hypothesis that expression of the BRCA2 gene may be suppressed in sporadic breast cancers by a mechanism that is associated with increased methylation of cytosine residues in the promoter region. Using a HpaII/MspI digestion-polymerase chain reaction based assay, the presence of 5-methylcytosine in three CpG dinucleotides within the BRCA2 promoter was assessed in 18 breast or ovarian cancer cell lines, in an SV40 large T antigen immortalized cell line derived from normal breast epithelial cells, in 64 primary sporadic breast cancers and peripheral blood leucocytes from these cases and in a number of other normal human tissues. Methylation was not detected in any of the tissues examined, suggesting that this mechanism of transcriptional repression is unlikely to explain the absence of somatic mutations in sporadic cancers.

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

Author information

Authors and Affiliations

1. Section of Molecular Carcinogenesis, Haddow Laboratories, Institute of Cancer Research, Sutton, Surrey, UK
   N Collins

Authors

1. N Collins
2. R Wooster
3. MR Stratton

Rights and permissions

About this article

Cite this article

Collins, N., Wooster, R. & Stratton, M. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.Br J Cancer 76, 1150–1156 (1997). https://doi.org/10.1038/bjc.1997.526

Download citation

• Issue Date: 01 November 1997
• DOI: https://doi.org/10.1038/bjc.1997.526

This article is cited by

• Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer

  • Rosa Murria Estal
  • Sarai Palanca Suela
  • Pascual Bolufer Gilabert
    Familial Cancer (2016)

• RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families

  • Martin J Larsen
  • Mads Thomassen
  • Anne-Marie Gerdes
    BMC Medical Genomics (2014)

• EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry

  • Anita L. Bane
  • Anna Marie Mulligan
  • Irene L. Andrulis
    Breast Cancer Research and Treatment (2011)

• Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers

  • Lindsay A. Brown
  • Karynn Johnson
  • David G. Huntsman
    Breast Cancer Research and Treatment (2010)

• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

  • Joshua Z Press
  • Alessandro De Luca
  • David G Huntsman
    BMC Cancer (2008)